The US health regulator has completed inspection of Lupin’s Nagpur facility, which manufactures oral solid products, without making any observations.
In a BSE filing today, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations.’’
Shares of Lupin were trading up by 1.72 per cent at Rs 764.75 on the BSE.